Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

oxaliplatin / Generic mfg.

NCT03750669: Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

Active, not recruiting

324

RoW

AG regimen, Nab-paclitaxel and Gemcitabine, mFolfirinox, Folic acid, 5- fluorouracil, irinotecan and oxaliplatin

Second Affiliated Hospital, School of Medicine, Zhejiang University

Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy

04/24

04/26

KONCLUDE, NCT02843191: Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy

Recruiting

358

RoW

Chemotherapy

Kyung Hee University Hospital at Gangdong, Korean Society of ColoProctology

Rectal Cancer

11/23

07/24

NCT05624138: The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy

Recruiting

RoW

Placebo tablets, Oxaliplatin, Fluorouracil, calcium leucovorin, Ketotifen Oral Tablet, ketotifen

Tanta University

Neuropathy;Peripheral

11/23

11/24

BRAZIL-TNT, NCT05081687: Brazilian Total Neoadjuvant Therapy Trial

Recruiting

150

RoW

Folfirinox, mFOLFIRINOX, FOLFOXIRI, 5-FU, oxaliplatin, irinotecan

Hospital Israelita Albert Einstein, Ministry of Health, Brazil

Colorectal Neoplasms

11/23

12/23

NCT01815853: Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer

Recruiting

620

RoW

Neoadjuvant Chemoradiotherapy, Neoadjuvant Chemotherapy, R0 D2 Gastrectomy, Adjuvant Chemotherapy

Sun Yat-sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Anhui Medical University, Liaoning Cancer Hospital & Institute, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangxi Medical University Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Zhejiang Cancer Hospital, First Hospital of China Medical University, First People's Hospital of Hangzhou

Gastric Cancer

12/23

12/25

PREACT, NCT03013010: Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy

Recruiting

682

RoW

Tegafur-Gimeracil-Oteracil Potassium, S-1, Chemoradiotherapy, radiochemotherapy, Gastric resection, Gastrectomy, Oxaliplatin

Shanghai Cancer Hospital, China, Fudan University, Ruijin Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Huadong Hospital

Stomach Neoplasm, GastroEsophageal Cancer, Adenocarcinoma, Locally Advanced Cancer, Chemoradiation

12/23

CISPD-4, NCT03983057: Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Recruiting

830

RoW

Anti-PD-1 monoclonal antibody

Zhejiang University

Pancreatic Cancer

12/23

12/24

DIRECT, NCT03899636: A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer

Recruiting

528

Modified FOLFIRINOX Regimen, NanoKnife System

Angiodynamics, Inc.

Stage III Pancreatic Cancer

12/23

NCT05680870: The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients

Not yet recruiting

Omeprazole, Omez

Aya Mohamed Sadek Elsaid

Chemotherapy Induced Peripheral Neuropathy

12/23

KEYNOTE 811, NCT03615326 / 2018-000224-34: Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

	From KEYNOTE-811 for patients with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma at ASCO 2021
	Jun 2021 - Jun 2021: From KEYNOTE-811 for patients with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma at ASCO 2021

Active, not recruiting

738

Europe, Japan, US, RoW

Pembrolizumab, Keytruda®, MK-3475, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab, Herceptin®

Merck Sharp & Dohme LLC

Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma

03/24

12/24

NCT06177041: M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Recruiting

486

RoW

M108 monoclonal antibody, Placebo, Oxaliplatin, Capecitabine

FutureGen Biopharmaceutical (Beijing) Co., Ltd

Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

01/27

04/27

NCT06201065: FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial

Recruiting

200

RoW

Hepatic arterial infusion chemotherapy, Lenvatinib, Toripalimab, oxaliplatin , fluorouracil, and leucovorin

Sun Yat-sen University

Hepatocellular Carcinoma

07/25

12/26

COLAGE, NCT03828227: QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.

Active, not recruiting

Europe

OPTIMOX-bevacizumab, Folinic acid (FA)-5-fluorouracil (5-FU)-oxaliplatin [OPTIMOX], Avastin, Capecitabine plus bevacizumab, capecitabine

GERCOR - Multidisciplinary Oncology Cooperative Group

Elderly Patients, Metastatic Colorectal Cancer, Quality of Life

11/23

09/24

NCT00217737: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Active, not recruiting

3610

Canada, US, RoW

Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669

National Cancer Institute (NCI)

Colon Mucinous Adenocarcinoma, Colon Signet Ring Cell Adenocarcinoma, Lynch Syndrome, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7

09/24

LAPIS, NCT03941093 / 2019-001925-28: Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer

Active, not recruiting

284

Europe, Canada, US, RoW

Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, FG-3019, Gemzar, Abraxane, Eloxitan, Leucovorin, Camptosar, 5-Fluracil, Efudex, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

FibroGen

Pancreatic Cancer Non-resectable

04/24

NCT04416854: The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer

Recruiting

627

RoW

resection of primary tumor, XELOX, mFOLFOX6

Fudan University

Metastatic Colon Cancer, Surgery

12/23

12/25

EA2183, NCT04248452: Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Recruiting

314

Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, folinic acid, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, Irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation

ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)

Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8

03/28

NCT04358354: Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer

Recruiting

388

RoW

Irinotecan, CPT-11, Oxaliplatin, LOHP, 5-fluorouracil, 5-FU

Sixth Affiliated Hospital, Sun Yat-sen University

Metastatic Gastric Cancer

12/23

12/24

NCT04687631: Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases

Recruiting

386

RoW

mFOLFOXIRI plus Cetuximab, mFOLFOXIRI Plus Bevacizumab

Fudan University

Colorectal Cancer, Liver Metastases

12/23

12/26

SOLARIS, NCT04094688: Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

Active, not recruiting

455

Bevacizumab, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride, Irinotecan, Cholecalciferol, Vitamin D3, Quality-of-Life Assessment, Questionnaire Administration

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)

Colorectal Adenocarcinoma

01/25

07/25

LIQUIPANC, NCT06391892: Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery

Recruiting

100

Europe

Neoadjuvant chemotherapy instead of upfront surgery, Experimental, Upfront surgery, Standard of care

Elisabethinen Hospital, Medical University Innsbruck

Pancreatic Cancer, Circulating Tumor Cell, Predictive Cancer Model

12/25

12/26

COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Active, not recruiting

610

RoW

AK104, Oxaliplatin, Capecitabine, Placebo

Akeso

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

08/24

04/25

CRC01, NCT06226857: Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer

Recruiting

355

RoW

Cetuximab, panitumumab

City Clinical Oncology Hospital No 1, Atlas Biomed, N.N. Blokhin National Medical Research Center of Oncology, Moscow MultidisciplinaryClinical Center Kommunarka

Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation

12/26

12/27

NCT06206733: ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Recruiting

780

RoW

ASKB589, Oxaliplatin, Capecitabine, Tislelizumab, Placebo

AskGene Pharma, Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

12/26

12/28

KN035-BTC, NCT03478488: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Recruiting

480

RoW

KN035 plus Gemcitabine & oxaliplatin, Experimental, Gemcitabine & oxaliplatin, Active Comparator

3D Medicines (Sichuan) Co., Ltd.

Biliary Tract Neoplasms

07/24

NeoCol, NCT01918527 / 2013-002363-26: Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer

Active, not recruiting

250

Europe

Capecitabine, Oxaliplatin

Vejle Hospital

Colon Cancer

06/23

02/25

ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting

774

Europe

LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine

Federation Francophone de Cancerologie Digestive

Colonic Adenocarcinoma

02/24

08/25

HR070803-307, NCT06217042: HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Not yet recruiting

524

RoW

HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, gemcitabine; capecitabine

Fudan University

Pancreatic Cancer

03/27

07/28

NCT05231382: Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma

Recruiting

426

RoW

Raltitrexed, oxaliplatin (SALOX) treatment, Oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment

Sun Yat-sen University

Hepatocellular Carcinoma

02/24

02/25

KEYNOTE-585, NCT03221426 / 2016-004408-76: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/)

Jan 2024 - Dec 2024: From P3 KEYNOTE-585 trial for patients with gastric and gastroesophageal junction adenocarcinoma

Active, not recruiting

1007

Europe, Canada, Japan, US, RoW

Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN®

Merck Sharp & Dohme LLC

Gastric Cancer, Gastroesophageal Junction Cancer

02/24

06/25

KEYNOTE-585 China Extension study, NCT04882241: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Active, not recruiting

115

RoW

Merck Sharp & Dohme LLC

Gastric Cancer, Gastroesophageal Junction Cancer

02/24

06/25

PelvEx II, NCT04389086: Induction Chemotherapy for Locally Recurrent Rectal Cancer

Recruiting

364

Europe

Combination drug, CAPOX, FOLFOX, FOLFIRI, Chemoradiotherapy, Surgery locally recurrent rectal cancer

Catharina Ziekenhuis Eindhoven

Recurrent Rectal Cancer

03/24

03/30

SHR-A1811-309, NCT06199973: Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan

Recruiting

120

RoW

SHR-A1811, TAS-102, Regorafenib , Fruquintinib

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Advanced Colorectal Cancer

04/26

06/26

NCT03362177 / 2017-002992-25: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

Active, not recruiting

162

Europe, Canada, US, RoW

Romiplostim, Placebo

Amgen

Chemotherapy-induced Thrombocytopenia

01/24

01/25

BECOME2, NCT04781270: mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Recruiting

308

RoW

mFOLFOXIRI regimen, mFOLFOX regimen, Bevacizumab

Fudan University

Colorectal Carcinoma, Liver Metastases

03/24

03/26

PARADIGM biomarker, NCT02394834: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Active, not recruiting

757

Japan

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab

Takeda

Colorectal Cancer

03/25

NCT04835064: Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

Not yet recruiting

600

Nab paclitaxel, Abraxane, Gemcitabine, Gemzar, mFOLFIRINOX, modified FOLFIRINOX regimen

Fudan University

Pancreatic Adenocarcinoma

04/24

12/24

NCT02912559: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Active, not recruiting

700

Europe, US

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Quality-of-Life Assessment, Quality of Life Assessment

National Cancer Institute (NCI)

Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8

04/25

NCT04370925: Efficacy of HIPEC in Patients With Colorectal Cancer at High Risk of Peritoneal Carcinomatosis

Recruiting

688

RoW

Radical colectomy, HIPEC, Systemic chemotherapy

Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Nanfang Hospital of Southern Medical University, Sun Yat-sen University, Sixth Affiliated Hospital, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangdong Provincial People's Hospital, Meizhou People's Hospital, First People's Hospital of Foshan, Shantou Central Hospital, Jiangmen Central Hospital, Shenzhen Second People's Hospital, Zhongshan People's Hospital, Guangdong, China, ZhuHai Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing Hospital, Beijing Cancer Hospital, Peking University People's Hospital, Fudan University, The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Cancer Hospital, First Affiliated Hospital of Chongqing Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Wuhan University, Sichuan Provincial People's Hospital, West China Hospital, The People's Hospital of Leshan, People’s Hospital of Deyang City, Hebei Medical University Fourth Hospital, The First Affiliated Hospital of Nanchang University, The Affiliated Hospital Of Southwest Medical University, The Affiliated Hospital of Xuzhou Medical University, People's Hospital of Guangxi, The Third People's Hospital of Chengdu, The Affiliated Tumor Hospital of Guangxi Medical University

Colorectal Cancer

04/24

04/26

KRYSTAL-10, NCT04793958 / 2020-004048-27: Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Active, not recruiting

461

Europe, Canada, US, RoW

MRTX849, Cetuximab, Erbitux, mFOLFOX6 Regimen, FOLFIRI Regimen

Mirati Therapeutics Inc.

Advanced Colorectal Cancer, Metastatic Colorectal Cancer

02/25

02/26

CIME, NCT06346197: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

Not yet recruiting

124

Europe

Balstilimab, Botensilimab, Folfox Protocol, XELOX, Nivolumab

Centre Leon Berard, Agenus Inc.

Gastric Cancer, MSI-H, Metastatic Cancer, Advanced Cancer

05/28

ChiCTR2000032992: A Phase III Randomized Controlled Trial of Comparison of Survival Benefit of Hepatic Arterial Infusion of Oxaliplatin plus Raltitrexed With Sorafenib for Patients With intermediate- and advanced-stage Hepatocellular Carcinoma

Not yet recruiting

130

Hepatic Arterial Infusion of Oxaliplatin plus Raltitrexed ;Oral sorafenib

Fujian Cancer Hospital; Fujian Cancer Hospital, Hospital funding

Hepatocellular carcinoma

ChanghaiH-PP09, NCT04931381: Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer

Recruiting

100

RoW

Chemotherapy guided by organoid drug sensitivity test

Changhai Hospital

Advanced Pancreatic Cancer

05/24

05/25

ChanghaiH-PP08, NCT04931394: Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer

Recruiting

200

RoW

Adjuvant chemotherapy guided by organoid drug sensitivity test

Changhai Hospital

Pancreatic Cancer

05/24

05/25

IROCAS, NCT02967289 / 2016-001491-29: IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting

Active, not recruiting

792

Europe, Canada

Irinotecan, Campto, Folfox Protocol, acid folinic + oxaliplatine + 5-FU

UNICANCER, Canadian Cancer Trials Group, GONO GROUP

Colon Cancer (High-risk Stage III: pT4N1 or pT1 to 4 N2)

06/24

06/27

TRIBE-C, NCT04230187: Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer

Recruiting

528

RoW

mFOLFOXIRI plus Bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, mFOLFOX6 Plus Bevacizumab

Yanhong Deng

Colorectal Cancer

06/24

06/26

NCT04351867: A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer

Not yet recruiting

196

RoW

docetaxel plus oxaliplatin and capecitabine, Three medicine combined, oxaliplatin plus capecitabine, Two medicine combined

LiNing

Stomach Neoplasms

06/24

RCNAC, NCT05201430: Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer

Recruiting

300

RoW

FOLFOXIRI, 5-Fu, Oxaliplatin, Irinotecan, Surgery, CapeOX, Capecitabine

Fudan University

Rectal Cancer

06/24

07/27

HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

12/24

07/25

NCT06411171: Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

Not yet recruiting

Pembrolizumab plus chemotherapy (FLOT), docetaxel, oxaliplatin, fluorouracil, and leucovorin (the FLOT regimen)

xiaohua li

Gastroesophageal Junction Cancer

09/25

09/28

DOSAGE, NCT06275958: Study: Upfront Dose-Reduced Chemotherapy in Older Patients With Metastatic Colorectal Cancer

Not yet recruiting

587

Europe

Doublet Chemotherapy, Standard Dose (100%), Doublet Chemotherapy, Dose-reduced (75%), Monotherapy, Standard Dose (100%), Monotherapy, Dose-reduced (75%)

Leiden University Medical Center, Dutch Colorectal Cancer Group, Stichting Darmkanker

Older Patients, Colorectal Cancer, Metastatic Cancer, Candidates for Palliative Chemotherapy

06/28

12/28

FOxTROT2France, NCT06293625: Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced But Resecable Colon Cancer in the Elderly of 70 Years Old or More

Recruiting

150

Europe

Folfox, Surgery

Centre Hospitalier Universitaire Dijon

Colon Cancer

06/32

CR-SEQUENCE, NCT03635021 / 2018-000347-60: Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer

Active, not recruiting

419

Europe

FOLFOX regimen, Panitumumab, Bevacizumab, FOLFIRI regimen

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Amgen

Colorectal Cancer

06/25

NCT05074966: The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts

Recruiting

314

RoW

Experimental: mXELOX plus cetuximab, Active Comparator: FOLFOX plus cetuximab

Chinese Academy of Medical Sciences

Colo-rectal Cancer

06/24

06/25

GRECCAR 15, NCT03879109: Chemotherapy Followed by Pelvic Reirradiation Versus Chemotherapy Alone as Pre-operative Treatment for Locally Recurrent Rectal Cancer

Active, not recruiting

Europe

Chemotherapy FOLFIRINOX, 6 cycles, Radiochemotherapy, Surgery

University Hospital, Bordeaux

Rectal Cancer

07/24

12/27

NCT03975049: Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Not yet recruiting

933

Chemoradiation, FOLFOXIRI Protocol, Folfox Protocol

Sixth Affiliated Hospital, Sun Yat-sen University

Rectal Cancer, Chemotherapy Effect

07/24

07/29

NEO-RT, NCT06205485: Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer

Not yet recruiting

250

Leucovorin, Oxaliplatin, Fluoruracil, Capecitabine, Radiation

Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, NRG Oncology, SWOG Cancer Research Network

Rectal Cancer

01/30

06/30

NCT02102789: A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis

Recruiting

142

RoW

mFOLFOX6, Oxaliplatin, Leucovorin, 5-fluorouracil, HAI, floxuridine (FUDR), dexamethasone

Yuhong Li

Metastatic Colorectal Cancer

08/24

12/24

RuCorT-01, NCT04103697: Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer

Enrolling by invitation

560

RoW

Capecitabine, Xeloda, Oxaliplatin, Radiotherapy, Rectal cancer surgery

Blokhin's Russian Cancer Research Center

Rectal Neoplasms Malignant, Rectum Carcinoma, Rectal Cancer

08/24

NCT03961841: Perioperative Combination Chemotherapy Versus Chemoradiation for Locally Advanced EGJ Adenocarcinoma

Not yet recruiting

900

chemoradiation with weekly 5Fu and oxaliplatin, Perioperative mFLOT, Perioperative FOLFOX

Sixth Affiliated Hospital, Sun Yat-sen University

Esophagogastric Junction Disorder, Neoplasms

08/24

08/29

ChiCTR2100048255: A randomized, open-label phase III clinical study on the efficacy and safety of oxaliplatin combined with capecitabine versus docetaxel combined with Seggio in the treatment of stage IIIc gastric cancer with postoperative adjuvant chemotherapy

Not yet recruiting

oxaliplatin plus capecitabine ;docetaxel plus S-1

Anhui Provincial Tumor Hospital; Anhui Provincial Tumor Hospital, self-raised

gastric cancer

NCT06017583: Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer

Recruiting

RoW

Tislelizumab, Capecitabine, Oxaliplatin, SIB-IMRT, IMRT

Yong Zhang,MD

Rectal Neoplasms

08/24

08/26

NCT04617821: AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Recruiting

300

RoW

Nab paclitaxel plus gemcitabine, AG regimen, mFOLFIRINOX, modified FOLFIRINOX regimen

Fudan University

Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma

09/24

COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting

202

Europe, US, RoW

177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)

ITM Solucin GmbH

Neuroendocrine Tumors

06/27

09/27

PROMENADE, NCT02974556: Proactive Management of Endoperitoneal Spread in Colonic Cancer

Not yet recruiting

140

Europe

Standard surgical treatment, Proactive management, Standard adjuvant systemic chemotherapy, adjuvant capecitabine and oxaliplatin (CAPOX), adjuvant 5-FU and oxaliplatin (FOLFOX)

University of Roma La Sapienza

Colon Cancer, Intraperitoneal Rectal Cancer

09/24

09/25

POLARGO, NCT04182204 / 2018-003727-10: A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting

270

Europe, Canada, US, RoW

Polatuzumab Vedotin, Rituximab, Mabthera; Rituxan, Gemcitabine, Oxaliplatin

Hoffmann-La Roche

Diffuse Large B-Cell Lymphoma

09/24

03/25

ECTX, NCT01460589: Early Commencement of Adjuvant Chemotherapy for Colon Cancer

Active, not recruiting

440

RoW

timing to initiate the adjuvant chemotherapy, early commencement of chemotherapy

Kyungpook National University Hospital

Colon Cancer

10/24

12/24

RuCorT-02, NCT04134897: Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer

Enrolling by invitation

316

RoW

Capecitabine, Xeloda, Oxaliplatin, Radiotherapy, Rectal cancer surgery

Blokhin's Russian Cancer Research Center

Rectal Neoplasms Malignant, Rectum Carcinoma, Rectal Cancer

10/24

RuCorT-03, NCT04135313: Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer

Enrolling by invitation

540

RoW

Capecitabine, Xeloda, Oxaliplatin, Radiotherapy, Rectal cancer surgery

Blokhin's Russian Cancer Research Center

Rectal Neoplasms Malignant, Rectum Carcinoma, Rectal Cancer

10/24

NCT04135781: Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Recruiting

616

RoW

nab paclitaxel, albumin bound paclitaxel, Tegafur, S-1, Oxaliplatin, Capecitabine

Zhejiang Cancer Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.

Stomach Cancer

10/24

TRIPLET-III, NCT05313282: A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification

Recruiting

140

RoW

Hepatic Arterial Infusion combined with Apatinib and Camrelizumab, Apatinib combined with Camrelizumab

Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd.

C-staged Hepatocellular Carcinoma in BCLC Classification

11/24

06/25

NCT05610332: Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes

Not yet recruiting

216

RoW

Camrelizumab, Albumin Taxol, FLOT scheme

Fujian Medical University

Locally Advanced Gastric Cancer

11/24

11/27

BREAKWATER, NCT04607421 / 2020-001288-99: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

	Jan 2025 - Dec 2025: Approval for 1L BRAFV600E metastatic CRC (based on BREAKWATER trial)
	Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023
	Jan 2023 - Jan 2023: Data from the safety lead-in portion of BREAKWATER trial in BRAF V600E-mutant mCRC at ASCO-GI 2023

Recruiting

815

Europe, Canada, Japan, US, RoW

Encorafenib, Braftovi, PF-07263896, LGX818, ONO-7702, Cetuximab, Erbitux, Oxaliplatin, Eloxatin, Irinotecan, Campostar, Leucovorin, Wellcovorin, Fusilev, Khapzory, 5-FU, Fluorouracil, Capecitabine, Xeloda, Bevacizumab, Zirabev

Pfizer, Ono Pharmaceutical Co. Ltd, Merck KGaA, Darmstadt, Germany, Eli Lilly and Company

Neoplasms

01/25

11/26

COMMIT, NCT02997228: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the Study

Recruiting

120

Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin, Folinic acid, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration

National Cancer Institute (NCI), NRG Oncology

Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7

11/24

NCT04595864: Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation

Recruiting

RoW

Transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU), TAI

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Hepatocellular Carcinoma, Liver Transplantation

11/24

10/26

PHITT, NCT03017326 / 2016-002828-85: Paediatric Hepatic International Tumour Trial

Active, not recruiting

450

Europe, RoW

Cisplatin, Doxorubicin, Carboplatin, 5Fluorouracil, Vincristine, Etoposide, Irinotecan, Gemcitabine, Oxaliplatin, Sorafenib

University of Birmingham, Fundació Institut Germans Trias i Pujol, University Hospital Munich, University Hospital, Bonn, University of Kiel, University Hospital Tuebingen, University of Padova, Ludwig-Maximilians - University of Munich, Medical University of Gdansk, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Motol University Hospital, Prague, Rennes University Hospital, Children's University Hospital, Ireland, University of Oslo, Princess Maxima Center for Pediatric Oncology, Andaluz Health Service, Swiss Pediatric Oncology Group, Gothia Forum - Center for Clinical Trial, The Leeds Teaching Hospitals NHS Trust, Bambino Gesù Hospital and Research Institute, Newcastle University Centre for Cancer, Newcastle, Experimental Cancer Medicine Centres, XenTech, Evry

Hepatoblastoma, Carcinoma, Hepatocellular

08/26

08/27

COPEC, NCT04922853: Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer

Recruiting

554

RoW

Capox chemotherapy

West China Hospital, The Third People's Hospital of Chengdu, Chengdu Fifth People's Hospital, Peking Union Medical College, Beijing Cancer Hospital, Sun Yat-sen University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Yunnan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Affiliated Hospital Of Guizhou Medical University, Sichuan Provincial People's Hospital, Nanchong Central Hospital, Dazhou Central Hospital, Leshan People's Hospital, GeneCast Biotechnology Co., Ltd.

Rectal Cancer, Neoadjuvant Chemotherapy

12/24

12/26

NCT05194878: Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Recruiting

840

RoW

neoadjuvant chemotherapyI, mFOLFOXIR, Colectomy, adjuvant chemotherapy, FOLFOX/CapeOX/Cape

Sun Yat-sen University

Colon Cancer Stage II, Colon Cancer Stage III

12/24

12/26

NCT05866172: HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC

Recruiting

264

RoW

HAIC, Zoledronic acid

Sun Yat-sen University

Hepatocellular Carcinoma

12/24

06/25

NeoFOL-R, NCT05529940: Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

Not yet recruiting

609

RoW

Folfirinox

Seoul National University Hospital, Seoul St. Mary's Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Gangnam Severance Hospital

Resectable Pancreatic Cancer, Neoadjuvant Chemotherapy, Effects of Chemotherapy

12/24

12/27

NCT05171660: Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Recruiting

436

RoW

Sintilimab Injection, bevacizumab, Oxaliplatin, Capecitabine, Control Test, XELOX + Bevacizumab

Second Affiliated Hospital, School of Medicine, Zhejiang University

Colorectal Cancer Stage IV

12/24

06/25

NCT05751850: HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Recruiting

778

RoW

HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, nab-paclitaxel; gemcitabine

Jiangsu HengRui Medicine Co., Ltd.

First-line Treatment of Advanced Pancreatic Cancer

12/24

12/25

HARVEST, NCT03500874: Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM

Terminated

RoW

FUDR, Floxuridine, Oxaliplatin, Xaliplatin, Leucovorin, Folinic Acid, 5FU, 5-Fluorouracil, Irinotecan, CPT-11

Sun Yat-sen University

Colorectal Cancer, Liver Metastases, HAI

08/21

NCT04233151: QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety

Recruiting

590

RoW

QL1203, Placebo, mFOLFOX6 regimen

Qilu Pharmaceutical Co., Ltd.

Metastatic Colorectal Cancer

12/24

07/25

NCT04854668: A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active, not recruiting

748

RoW

Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin, Capecitabine

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Metastatic Colorectal Cancer

12/24

12/25

NCT04787354: Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

Recruiting

976

RoW

Oxaliplatin, Capecitabine

Hallym University Medical Center

Gastric Cancer

12/24

12/27

NCT05264896: Perioperative FLOT vs Adjuvant XELOX for CA Stomach

Recruiting

110

RoW

5-FU, Leucovorin, Oxaliplatin, Docetaxel, XELOX

Chinese University of Hong Kong

Cancer of Stomach, Adenocarcinoma

12/24

12/27

FOBEAR, NCT04215731: Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer

Recruiting

500

RoW

Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab, Oxaliplatin, Irinotecan, 5-Fluorouracil, Leucovorin, Bevacizumab, Restaging, Concomitant Chemoradiotherapy, Surgery, Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging), Induction chemotherpay with FOLFOX

Yanhong Deng

Rectal Cancer

02/25

FANTASTIC, NCT04338191: mFOLFOXIRI Versus mFOLFOX6 as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer

Recruiting

638

RoW

mFOLFOXIRI adjuvant chemotherapy, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil, mFOLFOX6 adjuvant chemotherapy

Sun Yat-sen University

Colorectal Cancer

02/25

MATTERHORN, NCT04592913 / 2019-001555-40: Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

	Jan 2024 - Dec 2024: Data from MATTERHORN trial for gastric and gastroesophageal Cancer
	Jan 2024 - Dec 2024: Acceptance of regulatory submission for neo-adjuvant/adjuvant gastric (based on MATTERHORN trial)
	Jul 2020 - Dec 2020 : From trial for MDS

Active, not recruiting

958

Europe, Canada, Japan, US, RoW

Durvalumab, FLOT chemotherapy

AstraZeneca

Gastrointestinal Neoplasms, Esophagogastric Junction

10/25

09/27

NCT06049901: Nitazoxanide in Patients With Metastatic Colorectal Cancer

Recruiting

RoW

Nitazoxanide, Nanazoxid

Tanta University

Metastatic Colorectal Cancer

03/25

03/26

NCT04950322: A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Active, not recruiting

737

RoW

SHR-1701、CAPOX, Placebo、CAPOX

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Gastric or Gastroesophageal Junction Cancer

03/25

06/25

NCT04365036: A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)

Recruiting

207

RoW

Toripalimab, Pegaspargase, Gemcitabine, Oxaliplatin, Definitive intensity-modulated radiotherapy (IMRT)

Sun Yat-sen University

NK/T Cell Lymphoma Nos

04/25

06/25

PRECAM-R, NCT05752136: Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma

Recruiting

108

RoW

Envafolimab

Sir Run Run Shaw Hospital

Rectal Cancer

04/25

12/28

STARGLO, NCT04408638 / 2020-001021-31: A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

	Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
	Jan 2023 - Dec 2024: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for r/r DLBCL
	Feb 2023 - Dec 2023: Data readout from STARGLO trial in combination with gemcitabine and oxaliplatin for 2L+ DLBCL

Recruiting

270

Europe, US, RoW

Obinutuzumab, Glofitamab, Rituxumab, Tocilizumab, Gemcitabine, Oxaliplatin

Hoffmann-La Roche

Diffuse Large B-cell Lymphoma

04/25

SUNMO, NCT05171647: A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Jan 2023 - Dec 2024: Data from SUNMO trial in combination with polivy for 2L+ DLBCL

Recruiting

222

Canada, Japan, US, RoW

Mosunetuzumab, Polatuzumab vedotin, Tocilizumab, Rituximab, Gemcitabine, Oxaliplatin

Hoffmann-La Roche

Non-Hodgkin Lymphoma

05/25

11/27

NCT05954078: Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colorectal Cancer

Recruiting

340

RoW

mFOLFIRINOX adjuvant chemotherapy, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil, mFOLFOX6/XELOX adjuvant chemotherapy

Fudan University

High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation

06/26

06/28

CheckMate 8HW, NCT04008030 / 2018-000040-26: A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

	Jan 2024 - Dec 2024: Data readout from P3 CheckMate 8HW trial for 1L+ MSI High CRC
	Jan 2023 - Dec 2023: Submission in Japan in combination with Opdivo for 1L colorectal cancer (based on CHECKMATE 8HW trial)
	Jan 2023 - Dec 2023: Submission in Japan in combination with Yervoy for 1L colorectal cancer (based on CHECKMATE 8HW trial)

Recruiting

831

Europe, Canada, Japan, US, RoW

Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab, Nivolumab

Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd

Metastatic Colorectal Cancer

06/25

06/26

LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

	Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
	Sep 2021 - Dec 2021 : Submission for r/r DLBCL
	Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL

Recruiting

350

Europe, Canada, Japan, US, RoW

Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin

ADC Therapeutics S.A., ADC Therapeutics SA

Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma

06/25

06/28

GEMFOX, NCT04167007: FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX

Recruiting

400

Europe

Gemcitabine, FOLFOX

Assistance Publique - Hôpitaux de Paris

Pancreatic Adenocarcinoma

07/25



	Diseases Companies Products Productz Mechanisms of Action Sites